No benefit to remdesivir, HCQ, lopinavir, or interferon in large WHO trial of adults hospitalized with COVID-19 (Solidarity)

AdARRC™ March 1, 2021 Monday Weekly Update
No benefit to remdesivir, HCQ, lopinavir, or interferon in large WHO trial of adults hospitalized with COVID-19 (Solidarity)
No benefit to remdesivir, HCQ, lopinavir, or interferon in large WHO trial of adults hospitalized with COVID-19 (Solidarity)

Question

Are older antiviral drugs beneficial for adults hospitalized with COVID-19?

Conclusion

This large open-label randomized trial found no benefit to remdesivir, interferon, lopinavir, or hydroxychloroquine for adults hospitalized with COVID-19. The only possible benefit was seen with remdesivir in patients who required low-flow or no oxygen, but the absolute benefit, if any, was small.

Reference

WHO Solidarity Trial Consortium, Pan H, Peto R, et al. Repurposed antiviral drugs for Covid-19 interim WHO Solidarity trial results. N Engl J Med. Published online December 2, 2020. doi: 10.1056/NEJMoa2023184.

Share This Post!